BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2198 related articles for article (PubMed ID: 18651308)

  • 1. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
    Panizo MM; Reviákina V; Dolande M; Selgrad S
    Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Susceptibility to azoles and amphotericin B of isolates of Candida spp. Experience of a university health network, between 2004 and 2010].
    Porte L; León P; Gárate C; Guzmán AM; Labarca J; García P
    Rev Chilena Infectol; 2012 Apr; 29(2):149-55. PubMed ID: 22689028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution and antifungal susceptibility of Candida species causing nosocomial candiduria.
    Ozhak-Baysan B; Ogunc D; Colak D; Ongut G; Donmez L; Vural T; Gunseren F
    Med Mycol; 2012 Jul; 50(5):529-32. PubMed ID: 21988703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility of oral Candida to seven antifungal agents.
    Kuriyama T; Williams DW; Bagg J; Coulter WA; Ready D; Lewis MA
    Oral Microbiol Immunol; 2005 Dec; 20(6):349-53. PubMed ID: 16238594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifungal susceptibility of bloodstream yeasts isolated at a public children's hospital in Brazil: comparison of the Etest and the AFST-EUCAST microdilution method.
    Matsumoto FE; Dias AL; Melhem MS; Szeszs MW; Auler ME; Ruiz LS; Gonçalves da Silva E; Gandra RF; Paula CR
    Can J Microbiol; 2007 Dec; 53(12):1300-6. PubMed ID: 18059562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
    J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Susceptibility of yeasts to antifungal agents in Kaunas University of Medicine Hospital].
    Skrodeniene E; Dambrauskiene A; Vitkauskiene A
    Medicina (Kaunas); 2006; 42(4):294-9. PubMed ID: 16687901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Species distribution and drug susceptibilities of Candida isolates in TSARY 2010.
    Yang YL; Chen HT; Lin CC; Chu WL; Lo HJ;
    Diagn Microbiol Infect Dis; 2013 Jun; 76(2):182-6. PubMed ID: 23574935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and Antifungal Susceptibility of the Emerging Fungal Species,
    Sikora M; Kuthan R; Piskorska-Malolepsza K; Golas-Pradzynska M; Domański D; Augustynowicz-Kopeć E; Swoboda-Kopec E
    Pol J Microbiol; 2019 Sep; 68(3):303-308. PubMed ID: 31880875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital.
    Bedini A; Venturelli C; Mussini C; Guaraldi G; Codeluppi M; Borghi V; Rumpianesi F; Barchiesi F; Esposito R
    Clin Microbiol Infect; 2006 Jan; 12(1):75-80. PubMed ID: 16460550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antifungal susceptibility and distribution of Candida spp. isolates from the University Hospital in the municipality of Dourados, State of Mato Grosso do Sul, Brazil.
    Almeida AA; Mesquita CS; Svidzinski TI; Oliveira KM
    Rev Soc Bras Med Trop; 2013; 46(3):335-9. PubMed ID: 23856873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.
    González GM; Elizondo M; Ayala J
    J Clin Microbiol; 2008 Sep; 46(9):2902-5. PubMed ID: 18632907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.
    Xiao M; Fan X; Chen SC; Wang H; Sun ZY; Liao K; Chen SL; Yan Y; Kang M; Hu ZD; Chu YZ; Hu TS; Ni YX; Zou GL; Kong F; Xu YC
    J Antimicrob Chemother; 2015 Mar; 70(3):802-10. PubMed ID: 25473027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National surveillance of antifungal susceptibility of Candida species in South Korean hospitals.
    Yoo JI; Choi CW; Lee KM; Kim YK; Kim TU; Kim EC; Joo SI; Yun SH; Lee YS; Kim BS
    Med Mycol; 2009; 47(5):554-8. PubMed ID: 18819023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 110.